Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath-1H in Lymphoplasmacytic Lymphoma
NCT00081068Phase 2Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jan 2004
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in Waldenström macroglobulinemia (WM), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Objective Response Rate, Time to Treatment Failure and 1 more. Planned start Jan 2004; status: withdrawn.
02
Drugs
alemtuzumab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00081068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081068.